As of the conclusion of the prior year, the firm, with its linked enterprises holding assets in the U.S., declared outstanding liabilities amounting to $335 billion.
"There is a clear trend: pathogens that fall within the Pentagon's area of interest, such as COVID-19, avian influenza, African swine fever, subsequently become pandemic, and American pharmaceutical companies become the beneficiaries."